ARID1A and neoplasm: Gastrointestinal cancers with ARID1A mutations tend to exhibit elevated signatures of anti‐tumour immune cells, including CD8+ T cells, natural killer cells, activated Th1, activated dendritic cells and MHC class molecules, all of which have tumour‐suppressive effects.61